neotype™ cancer profiles - brochure · neotype™ cancer profiles are multi-method test panels...
TRANSCRIPT
The next generation ofdiagnostic, prognostic, and
therapeutic assessment
Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors
Anatomic Pathology
MolecularFISH
NeoTYPE™ Cancer Profiles
2 • NeoGenomics Laboratories
NeoTYPE™ Cancer Profiles are multi-method test panels based on next-gen sequencing that identify the genetic changes most significant for
• Confirming diagnosis • Disease classification• Assessing prognosis• Predicting response to therapy• Identifying new therapeutic approaches• Identifying clinical trial opportunities
When to testThese Profiles highlight high-frequency recurrent mutations and provide a practical approach to understanding the cancer’s biology for the most effective patient management. Tests are appropriate for:
• First-line gene testing • Patients with an unusual clinical presentation• Developing therapeutic strategies• Identifying clinical trials• Patients resistant to conventional therapy
NeoGenomics Laboratories • 3
Benefits and Advantages of Targeted Profile Testing• Targeted
Test design is tailored to driver mutations in specific tumors.
• Actionable All genes have clinical significance when mutated.
• ComprehensiveUnique reporting of diagnostic, prognostic, and therapeutic implications.
• FlexibleChoose ‘as-shown’ or as add on.
• EfficientWith fast TAT’s, NeoTYPEs can replace first-line single-gene testing.
• QuantitativeReporting of mutant allele frequencies is useful for monitoring.
• Cost-effective
Flexibility, Performance, Selection Next-generation sequencing (NGS) is widely known for its high sensitivity which aids detection of abnormalities in small biopsies, minimal residual disease, and subclonal heterogeneity. The NeoTYPE next-gen suite offers an additional set of distinct benefits focusing on driver genes and actionable abnormalities, which includes point mutations, indels, translocations, and more.
NeoTYPE Cancer Profiles simplify the laboratory testing process and provide key diagnostic, prognostic, and predictive information you need for up-to-date and fully informed decision-making.
4 • NeoGenomics Laboratories
Sample Report
Sample
NeoGenomics Laboratories • 5
Broad Reach Hematologic ProfilesMyeloid Disorders (54 Molecular)
ABL1 ASXL1 ATRX BCOR BCORL1 BRAF
CALR CBL CBLB CBLC CDKN2A CEBPA
CSF3R CUX1 DNMT3A ETV6 EZH2 FBXW7
FLT3 GATA1 GATA2 GNAS HRAS IDH1
IDH2 IKZF1 JAK2 V617F JAK2 Exon 12+14 JAK3
KDM6A KIT KRAS MLL MPL MYD88
NOTCH1 NPM1 NRAS PDGFRA PHF6 PTEN
PTPN11 RAD21 RUNX1 SETBP1 SF3B1 SMC1A
SMC3 SRSF2 STAG2 TET2 TP53 U2AF1
WT1 ZRSR2
Broad Reach Solid Tumor ProfilesPrecision (48 Molecular, 1 IHC)
ABL1 AKT1 ALK APC ATM
BRAF CDH1 CDKN2A CSF1R CTNNB1
EGFR ERBB2 ERBB4 FBXW7 FGFR1
FGFR2 FGFR3 FLT3 GNA11 GNAQ
GNAS HNF1A HRAS IDH1 JAK2
JAK3 KDR KIT KRAS MET
MLH1 MPL NOTCH1 NPM1 NRAS
PDGFRA PIK3CA PTEN PTPN11 RB1
RET SMAD4 SMARCB1 SMO SRC
STK11 TP53 VHL PD-L1 IHC
Discovery (315 Molecular, 9 FISH, 1 IHC)Next-gen sequencing of 315 genes + 9 FISH + PD-L1 IHC. This is an actionable discovery panel suitable for clinical research applications and wide-spectrum patient testing. See website or handout for complete test details.
Cancer Exome (4813 Molecular)Next-gen sequencing of 4813 cancer-related genes. Testing is recommended for those interested in academic or clinical research. See website for complete test details, or call our Client Services Team at 866.776.5907.
Cancer-Specific Hematologic ProfilesAITL/Peripheral T-Cell Lymphoma Profile (5 Molecular)
DNMT3A IDH1 IDH2 RHOA TET2
AML Favorable-Risk (2 Molecular)
FLT3 KIT
AML Prognostic (27 Molecular)
ASXL1 BCOR BRAF
CEBPA CSF3RDNMT3A
ETV6EZH2 FLT3
HRAS IDH1IDH2
JAK2 KIT KRAS
MLL NPM1 NRAS
PDGFRA PHF6 PTPN11
RUNX1SETBP1STAG2
TET2TP53WT1
CLL Prognostic (5 Molecular, 1 FISH Panel)
IgVH Mutation MYD88 NOTCH1 SF3B1 TP53 CLL FISH Panel
JMML (16 Molecular)BRAF CBL
CEBPA FLT3
HRAS JAK2 V617F
JAK2 Exon 12+14JAK3
KIT KRAS
NPM1 NRAS
PDGFRA PTEN
PTPN11SETBP1
Lymphoma (8 Molecular)
BCL1 BCL2 BRAF CARD11 CD79B EZH2 MYD88 NRAS
MDS/CMML (32 Molecular)
ASXL1 BCORBCORL1
BRAFCBLCEBPA
CUX1DNMT3AETV6
EZH2 FLT3 HRAS
IDH1 IDH2 JAK2 V617F
JAK2 Exon 12+14 KIT
KRAS NPM1 NRAS
PDGFRA PTEN PTPN11
RUNX1SETBP1SF3B1
SRSF2 STAG2 TET2
TP53 U2AF1ZRSR2
MPN (25 Molecular)
ABL1 ASXL1BRAF
CALR CEBPA CSF3R
EZH2 FLT3 HRAS
IDH1IDH2JAK2 V617F
JAK2 Exon 12+14 KIT KRAS
MPL NPM1 NRAS
PDGFRA PTEN PTPN11
SETBP1SRSF2 TET2
U2AF1
NeoGenomics Laboratories • 6
Cancer-Specific Solid Tumor ProfilesBrain (22 Molecular, 5 FISH, 1 IHC)
AKT1ATRXBRAFCTNNB1
EGFREGFRvlll Analysis ERBB2
ERBB4FGFR1FGFR2FGFR3
IDH1 IDH2 MET
MGMT PromoterMethylation PIK3CA
PTENSMAD4SMOSRC
TERT Promoter TP531p/19q Deletion FISH
BRAF FISHMET FISHMYCN FISHPTEN FISH
PD-L1 IHC
Breast (22 Molecular, 3 FISH, 1 IHC)AKT1BRAFBRCA1
BRCA2CTNNB1EGFR
ERBB2ERBB4 FGFR1
FGFR2FGFR3HRAS
KIT KRASMET
NRASPIK3CAPTEN
SMAD4SMOSRC
TP53HER2 FISH MET FISH
PTEN FISHPD-L1 IHC
Cervical (22 Molecular, 2 FISH, 1 IHC)AKT1BRAFCTNNB1
EGFRERBB2ERBB4
FGFR1FGFR2FGFR3
HRASJAK3KRAS
METNOTCH1NRAS
PDGFRAPIK3CAPTEN
SMAD4 SMO SRC
TP53MET FISHPTEN FISH
PD-L1 IHC
Colorectal (24 Molecular, 2 FISH, 1 IHC)
AKT1APC BRAFEGFR
ERBB2 ERBB4FGFR1FGFR2
FGFR3 HRAS JAK3 KIT
KRAS MET Microsatellite Instability (MSI)
MLH1 Promoter MethylationNOTCH1NRASPDGFRA
PIK3CAPTENSMO SRC
TP53 MET FISHPTEN FISHPD-L1 IHC
Endometrial (21 Molecular, 2 FISH, 1 IHC)
AKT1BRAFEGFR
FGFR1FGFR2FGFR3
HRAS JAK3 KIT
KRAS METMicrosatellite Instability (MSI)
NRASPDGFRAPIK3CA
PTENPTPN11SMAD4
SMOSRC TP53
MET FISHPTEN FISHPD-L1 IHC
Esophageal (22 Molecular, 3 FISH, 1 IHC)
AKT1BRAFCTNNB1ERBB2
ERBB4FGFR1FGFR2FGFR3
HRASJAK3 KITKRAS
METNOTCH1NRASPDGFRA
PIK3CAPTENSMAD4SMO
SRC TP53HER2 FISHMET FISH
PTEN FISHPD-L1 IHC
Gastric (22 Molecular, 3 FISH, 1 IHC)
AKT1BRAFEGFR
ERBB2ERBB4FGFR1
FGFR2FGFR3HRAS
JAK3 KITKRAS
METNOTCH1NRAS
PDGFRAPIK3CAPTEN
SMAD4SMOSRC
TP53HER2 FISHMET FISH
PTEN FISH PD-L1 IHC
GIST (11 Molecular, 1 IHC)AKT1BRAF
CTNNB1ERBB2
ERBB4FGFR1
FGFR2FGFR3
KITPDGFRA
SRCPD-L1 IHC
Head & Neck (25 Molecular, 2 FISH, 1 IHC)
AKT1ATMBRAF
CDKN2ACTNNB1EGFR
ERBB2 ERBB4FGFR1
FGFR2FGFR3HRAS
IDH1IDH2 KRAS
METNOTCH1NRAS
PIK3CAPTENRB
SMOSRC TP53
MET FISHPTEN FISHPD-L1 IHC
HPV DNA Tissue Test
Liver/Biliary (24 Molecular, 2 FISH, 1 IHC)
AKT1ATMBRAF
CDKN2ACTNNB1EGFR
ERBB2ERBB4FGFR1
FGFR2FGFR3 HRAS
IDH1IDH2KRAS
METNOTCH1NRAS
PIK3CAPTENSMAD4
SMOSRCTP53
MET FISHPTEN FISHPD-L1 IHC
Liposarcoma Fusion Profile (5 Molecular, 1 FISH)
COL1A2-PLAG1 EWSR1-DDIT3 FUS-DDIT3 HMGA2-LPP LPP-HMGA2 MDM2 FISH
Lung (21 Molecular, 6 FISH, 1 IHC)
AKT1BRAF EGFR
ERBB2ERBB4FGFR1
FGFR2FGFR3 KIT
KRASMET
MET Exon 14 Deletion AnalysisNOTCH1
NRASPDGFRAPIK3CA
PTEN SMAD4 SMO
SRC TP53 ALK FISH
HER2 FISHMET FISHPTEN FISH
RET FISHROS1 FISH PD-L1 IHC
Melanoma (17 Molecular, 1 FISH, 1 IHC)
AKT1BRAF
CTNNB1EGFR
ERBB2ERBB4
FGFR1 FGFR2
FGFR3GNAQ
KITNRAS
PDGFRAPTEN
SMO SRC
TERT Promoter
PTEN FISHPD-L1 IHC
Other Solid Tumor (24 Molecular, 2 FISH, 1 IHC)AKT1 BRAF EGFR
FGFR1FGFR2FGFR3
GNASHRASIDH1
IDH2 JAK3KIT
KRASMETNOTCH1
NRASPDGFRAPIK3CA
PTEN PTPN11SMAD4
SMO SRC TP53
MET FISHPTEN FISHPD-L1 IHC
Ovarian (22 Molecular, 2 FISH, 1 IHC)AKT1BRAF BRCA1
BRCA2CTNNB1EGFR
ERBB2 ERBB4 FGFR1
FGFR2FGFR3 HRAS
JAK3 KRAS MET
NRASPIK3CAPTEN
SMAD4 SMOSRC
TP53 MET FISHPTEN FISH
PD-L1 IHC
Pancreas (22 Molecular, 3 FISH, 1 IHC)AKT1 BRAF BRCA1
BRCA2 EGFR ERBB2
ERBB4 FGFR1FGFR2
FGFR3 HRAS KIT
KRASMETNOTCH1
NRASPDGFRAPIK3CA
PTENSMOSRC
TP53HER2 FISHMET FISH
PTEN FISHPD-L1 IHC
Soft Tissue (19 Molecular, 2 FISH, 1 IHC)
AKT1 BRAF FGFR1
FGFR2 FGFR3GNAS
HRAS JAK3KIT
KRASMETNRAS
PDGFRAPIK3CA PTEN
SMAD4SMOSRC
TP53MET FISHPTEN FISH
PD-L1 IHC
Thyroid (16 Molecular, 2 FISH, 1 IHC)
AKT1 ALK
BRAFCTNNB1
ERBB2ERBB4
HRAS KRAS
METNRAS
PIK3CARET
SMAD4SMO
SRC TERT Promoter
MET FISHRET FISH
PD-L1 IHC
Options for CustomizationAdd-OnsAny genes in the 54-gene Myeloid Disorders Profile may be added to any of the Hematologic Diseases Profiles.Any genes in the 48-gene Precision Profile for Solid Tumors may be added to any of the other Solid Tumor Profiles.Results of testing for added genes will be included in the comprehensive NeoTYPE report for that Profile.
Tech-Only FISHThis option is available to pathology clients who want to perform the professional components of any FISH tests within a Profile. These clients should order the component FISH tests as tech-only in combination with the molecular portion of the Profile.
NeoGenomics Laboratories • 7
12701 Commonwealth Dr., Suite 9Fort Myers, FL 33913 Phone: 866.776.5907/ Fax: 239.690.4237 neogenomics.com© 2017 NeoGenomics Laboratories, Inc. All Rights Reserved.All other trademarks are the property of their respective owners.Rev. 030117
Ordering InformationSpecimen options:• Peripheral blood• Bone marrow aspirate• Fresh tissue• FFPE slides or block
TAT: 10-22 days (varies by Profile)
Billing: NeoGenomics offers institutional and third-party billing.
New tests are in development. Sign up at www.neogenomics.com to be notified.
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-approved laboratories.
Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publication with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.